https://www.solosoft.dev/tags/radio-darpin/Recent content in Radio-DARPin on SoloSoftHugoen-ushttps://www.solosoft.dev/trends/2026-04-20-molecular-partners-presents-three-posters-at-aacr-/Mon, 01 Jan 0001 00:00:00 +0000https://www.solosoft.dev/trends/2026-04-20-molecular-partners-presents-three-posters-at-aacr-/<h2 id="how-is-the-darpin-platform-moving-from-technology-showcase-to-product-pipeline-at-aacr">How is the DARPin Platform Moving from &ldquo;Technology Showcase&rdquo; to &ldquo;Product Pipeline&rdquo; at AACR?</h2> <p><strong>Answer Capsule:</strong> The data from AACR 2026 shows that Molecular Partners has successfully translated DARPin&rsquo;s technical features into product prototypes with clear clinical differentiation advantages. MP0632 and MP0712 address the core pain points of current immunotherapies and radiotherapies: off-target toxicity and tumor delivery efficiency. This means DARPin is no longer just a sophisticated molecule in the lab but a practical weapon with the potential to carve out new pathways in the crowded tumor therapy market.</p> <p>In recent years, discussions in the biotech community about DARPin (Designed Ankyrin Repeat Proteins) have largely revolved around their excellent physicochemical properties: small size, high stability, and ease of assembly into multispecific formats. However, properties do not equal value. It was only with the emergence of data for MP0632 and MP0712 that we clearly saw how these properties are systematically engineered to solve real-world clinical problems.</p>